Key facts
- ChainGen Bio’s last known valuation is $35.9M (Aug 2025).
- It has raised $10.4M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Innoangel Fund, Legend Capital, TusStar Incubator, YuanBio Venture Capital, Frees Fund — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for ChainGen Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for ChainGen Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ChainGen Bio
Developer of targeted therapeutic modalities designed to deliver biologically active agents to specific tissues implicated in neurological and neuromuscular disorders. The company offers engineered receptor binding components, specialized conjugation methods, extrahepatic targeting architectures, and platforms for transporting diverse therapeutic payloads across physiological barriers, enabling researchers, clinicians, and drug development organizations to pursue disease-modifying interventions with greater biological accuracy and functional control.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- chaingenbio.com/
- Ownership
- Privately Held (backing)
ChainGen Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ChainGen Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ChainGen Bio in its N-PORT filings yet. We sweep new filings monthly.